Features of the Course of Arterial Hypertension in the Era of the COVID-19 Pandemic: Common Pathogenetic Links Between Hypertension and SARS-CoV-2
https://doi.org/10.18087/cardio.2024.4.n2525
Abstract
The aim of this review was to present the mechanism of infection with severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) and its possible effect on the course of arterial hypertension. Another aim was to evaluate the relationship of the renin-angiotensin-aldosterone system with the pathogenetic stages of infection caused by SARS-CoV-2 virus.
Supporting agencies: No conflict of interest is reported.
About the Authors
S. A. Berns
National Medical Research Center of Therapy and Preventive Medicine
Russian Federation
Russian Federation
Dr. Sci. (Med.), Рrofessor at the Department of Therapy and General Medical Practice, Head of the Department for the Study of Pathogenetic Aspects of Aging at the National Medical Research Center for therapy and Preventive Medicine,
Moscow, Russia
M. S. Leontyeva
Inozemtsev Municipal Clinical Hospital
Russian Federation
Russian Federation
general practitioner, head of therapy department, GBUZ «City Clinical Hospital. F.I. Inozemtsev DZM»,
Moscow, Russia
E. V. Tavlueva
National Medical Research Center of Therapy and Preventive Medicine; Inozemtsev Municipal Clinical Hospital
Russian Federation
Russian Federation
Dr. Sci. (Med.), Head of the Regional Vascular Center GBUZ «City Clinical Hospital. F.I. Inozemtsev DZM», Рrofessor at the Department of Cardiology, leading researcher of the Department for the Study of Pathogenetic Aspects of Aging at the National Medical Research Center for therapy and Preventive Medicine,
Moscow, Russia
V. S. Bashnyak
National Medical Research Center of Therapy and Preventive Medicine
Russian Federation
Russian Federation
MD, Cardiologist, Postgraduate Student, laboratory assistant researcher of the Department for the Study of Pathogenetic Aspects of Aging at the National Medical Research Center for Therapy and Preventive Medicine
Moscow, Russia
O. M. Drapkina
National Medical Research Center of Therapy and Preventive Medicine
Russian Federation
Russian Federation
Dr. Sci. (Med.), Рrof., Academician of the Russian Academy of Sciences, Chief Internal Medicine and General Practice Specialist of the Ministry of Health of the Russian Federation, Head of National Medical Research Center for therapy and Preventive Medicine,
Moscow, Russia
References
1. World Health Organization. Coronavirus disease (COVID-19) pandemic. [Internet] Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
2. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. [Internet] Available at: https://covid19.who.int
3. United Nations. WHO: 1.28 billion people suffer from hypertension, more than half of them are not receiving treatment. [Internet] 2021. Available at: https://news.un.org/ru/story/2021/08/1408782
4. Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S et al. Management of COVID-19: the Zhejiang experience. Zhejiang Da Xue Xue Bao. Yi Xue Ban. 2020;49(2):147–57. DOI: 10.3785/j.issn.1008-9292.2020.02.02
5. Böger B, Fachi MM, Vilhena RO, Cobre AF, Tonin FS, Pontarolo R. Systematic review with meta-analysis of the accuracy of diagnostic tests for COVID-19. American Journal of Infection Control. 2021;49(1):21–9. DOI: 10.1016/j.ajic.2020.07.011
6. Ivannikov A.A., Esaulenko A.N., Vasilchenko M.K., Alidzhanova Kh.G., Petrikov S.S. COVID-19 and Cardiovascular System. Part II. Post-COVID Syndrome. Russian Sklifosovsky Journal “Emergency Medical Care”. 2021;10(2):248–58. DOI: 10.23934/2223-9022-2021-10-2-248-258
7. Zolotovskaya I.A., Gimatdinova G.R., Davydkin I.L. Arterial hypertension in patients who have undergone COVID-19: features and possibilities of blood pressure correction. Prevention Medicine. 2022;25(1):63–70. DOI: 10.17116/profmed20222501163
8. Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I. et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):149–218. DOI: 10.15829/1560-4071-2020-3-3786
9. Islam N, Lacey B, Shabnam S, Erzurumluoglu AM, Dambha-Miller H, Chowell G et al. Social inequality and the syndemic of chronic disease and COVID-19: county-level analysis in the USA. Journal of Epidemiology and Community Health. 2021;75(6):496–500. DOI: 10.1136/jech-2020-215626
10. Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nature Reviews Cardiology. 2020;17(9):543–58. DOI: 10.1038/s41569-020-0413-9
11. Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. European Heart Journal. 2020;41(32):3038–44. DOI: 10.1093/eurheartj/ehaa623
12. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovascular Research. 2020;116(10):1666–87. DOI: 10.1093/cvr/cvaa106
13. Zagidullin N.Sh., Gareeva D.F., Ishmetov V.Sh., Pavlov A.V., Plotnikova M.R., Pushkareva A.E. et al. Renin-angiotensin-aldosterone system in new coronavirus infection 2019. Arterial Hypertension. 2020;26(3):240–7. DOI: 10.18705/1607-419X-2020-26-3-240-247
14. Petrikov S.S., Tyrov I.A., Perminov A.Yu., Fomenko N.S. Organizational and Informational Support for the Treatment of Patients With COVID-19 in a Multidisciplinary Emergency Hospital. Russian Sklifosovsky Journal “Emergency Medical Care”. 2020;9(3):308–13. DOI: 10.23934/2223-9022-2020-9-3-308-313
15. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. Journal of Clinical Medicine. 2020;9(5):1417. DOI: 10.3390/jcm9051417
16. Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation. Thrombosis Research. 2020;190:62. DOI: 10.1016/j.thromres.2020.04.014
17. Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. American Journal of Hypertension. 2020;33(5):373–4. DOI: 10.1093/ajh/hpaa057
18. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. DOI: 10.1136/bmj.m1091
19. Guan W, Liang W, Zhao Y, Liang H, Chen Z, Li Y et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. European Respiratory Journal. 2020;55(5):2000547. DOI: 10.1183/13993003.00547-2020
20. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054–62. DOI: 10.1016/S0140-6736(20)30566-3
21. Durvasula R, Wellington T, McNamara E, Watnick S. COVID-19 and Kidney Failure in the Acute Care Setting: Our Experience From Seattle. American Journal of Kidney Diseases. 2020;76(1):4–6. DOI: 10.1053/j.ajkd.2020.04.001
22. Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nature Reviews Nephrology. 2020;16(6):308–10. DOI: 10.1038/s41581-020-0284-7
23. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurology. 2020;77(6):683–90. DOI: 10.1001/jamaneurol.2020.1127
24. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. The Lancet. 2020;395(10237):1607–8. DOI: 10.1016/S0140-6736(20)31094-1
25. Golovkin A.S., Kudryavtsev I.V., Dmitriev A.V., Kalinina O.V. Fibrosis in the cardiovascular and respiratory systems after covid-19: a contribution of immune factors and genetic predisposition. Russian Journal of Cardiology. 2020;25(10):214–20. DOI: 10.15829/1560-4071-2020-4087
26. Larina V.N., Golovko M.G., Larin V.G. Possible Effects of Coronavirus Infection (COVID-19) on the Cardiovascular System. Bulletin of RSMU. 2020;2:5–13. DOI: 10.24075/vrgmu.2020.020
27. Corman VM, Lienau J, Witzenrath M. Coronaviruses as the cause of respiratory infections. Der Internist. 2019;60(11):1136–45. DOI: 10.1007/s00108-019-00671-5
28. Srivastava SP, Goodwin JE, Kanasaki K, Koya D. Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs. Genes. 2020;11(2):211. DOI: 10.3390/genes11020211
29. Bubnova M.G., Aronov D.M. COVID-19 and cardiovascular diseases: from epidemiology to rehabilitation. Pulmonologiya. 2020;30(5):688–99. DOI: 10.18093/0869-0189-2020-30-5-688-699
30. Xegay L.N., Sayfullaeva S.A., Abdurahimov A.Kh. The role of the components of the renin-angiotensin-aldosterone system in the clinical manifestations of COVID-19. Re-health journal. 2021;1(9):220–8. DOI: 10.24411/2181-0443/2021-10038
31. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB et al. Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19. New England Journal of Medicine. 2020;382(25):2441–8. DOI: 10.1056/NEJMoa2008975
32. de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. The Lancet. 2020;395(10238):1705–14. DOI: 10.1016/S0140-6736(20)31030-8
33. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TM-PRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. DOI: 10.1016/j.cell.2020.02.052
34. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–3. DOI: 10.1126/science.abb2507
35. Vikulova O.K., Zuraeva Z.T., Nikankina L.V., Shestakova M.V. The role of renin-angiotensin system and angiotensin-converting enzyme 2 (ACE2) in the development and course of viral infection COVID-19 in patients with diabetes mellitus. Diabetes mellitus. 2020;23(3):242–9. DOI: 10.14341/DM12501
36. Shlyakho E.V., Konradi A.O., Arutyunov G.P., Arutyunov A.G., Bautin A.E., Boytsov S.A. et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):129–48. DOI: 10.15829/1560-4071-2020-3-3801
37. Jessup JA, Brosnihan KB, Gallagher PE, Chappell MC, Ferrario CM. Differential effect of low-dose thiazides on the renin angiotensin system in genetically hypertensive and normotensive rats. Journal of the American Society of Hypertension. 2008;2(2):106–15. DOI: 10.1016/j.jash.2007.10.005
38. Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T et al. Mineralocorticoid Receptor Blocker Increases Angiotensin-Converting Enzyme 2 Activity in Congestive Heart Failure Patients. Circulation Research. 2005;97(9):946–53. DOI: 10.1161/01.RES.0000187500.24964.7A
39. Cadegiani FA, Wambier CG, Goren A. Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19. Frontiers in Medicine. 2020;7:453. DOI: 10.3389/fmed.2020.00453
40. Villard O, Morquin D, Molinari N, Raingeard I, Nagot N, Cristol J-P et al. The Plasmatic Aldosterone and C-Reactive Protein Levels, and the Severity of Covid-19: The Dyhor-19 Study. Journal of Clinical Medicine. 2020;9(7):2315. DOI: 10.3390/jcm9072315
41. Kuba K, Imai Y, Penninger JM. Multiple Functions of Angiotensin-Converting Enzyme 2 and Its Relevance in Cardiovascular Diseases. Circulation Journal. 2013;77(2):301–8. DOI: 10.1253/circj.CJ-12-1544
42. Kanorskiy S.G. Treatment of hypertension during the COVID-19 pandemic: questions about the blockade of the renin-angiotensin-aldosterone system. Medical Council. 2021;4:59–67. DOI: 10.21518/2079-701X2021-4-59-67
43. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–Angiotensin–Aldosterone System Blockers and the Risk of Covid-19. New England Journal of Medicine. 2020;382(25):2431–40. DOI: 10.1056/NEJMoa2006923
44. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. New England Journal of Medicine. 2020;382(17):1653–9. DOI: 10.1056/NEJMsr2005760
45. Brojakowska A, Narula J, Shimony R, Bander J. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System. Journal of the American College of Cardiology. 2020;75(24):3085–95. DOI: 10.1016/j.jacc.2020.04.028
Review
For citations:
Berns S.A., Leontyeva M.S., Tavlueva E.V., Bashnyak V.S., Drapkina O.M. Features of the Course of Arterial Hypertension in the Era of the COVID-19 Pandemic: Common Pathogenetic Links Between Hypertension and SARS-CoV-2. Kardiologiia. 2024;64(4):72-78. (In Russ.) https://doi.org/10.18087/cardio.2024.4.n2525
Views:
764
Email this article 
Post a Comment 
